{"url_path":"/sec/clpt/10-q/2026/item-1","section_key":"item-1","section_title":"Item 1 LEGAL PROCEEDINGS.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1285550/0001193125-26-221890-index.html","accession_number":"0001193125-26-221890","cik":"0001285550","ticker":"CLPT","issuer_name":"ClearPoint Neuro, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1285550/0001193125-26-221890-index.html","primary_entity_key":"0001285550","primary_entity_name":"ClearPoint Neuro, Inc."},"word_count":106,"has_tables":true,"body_markdown":"ITEM 1. LEGAL PROCEEDINGS.\n\nIn the ordinary course of our business, we may be subject to various claims, pending and potential legal actions for damages, investigations relating to governmental laws and regulations and other matters arising out of the normal conduct of our business. Regardless of outcome, litigation and other legal proceedings can have an adverse impact on us because of defense and settlement costs, diversions of management resources and other factors. As of the date of filing this Quarterly Report, we are not aware of any material pending legal proceeding to which we are a party or to which any of our property is subject."}